Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.

NCT07912164 is registered in ClinicalTrials.gov with Human Biome S.A. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07912164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.
Lead sponsor
Human Biome S.A.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2027
Enrollment
68 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aging and cognitive health, aging, healthy, fecal microbiota transplantation (fmt), inflammaging, inflammation, longevity, metabolic syndrome

Arms

As registered; 2 arms.

  • MBiotix HBI Caps ExperimentalFecal microbiota transplantation delivery through oral capsules (HBI MBiotix Caps)

    MBiotix HBI Caps (FMT capsules) + Preparation antibiotics (Neomycin and Metronidazole) + Standard bowel cleansing (Macrogols). Participants receive targeted preparation antibiotics followed by bowel cleansing, and then a multi-dose regimen of fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) in an initial induction phase and subsequent booster cycles.

  • Placebo Placebo comparatorPLACEBO for Fecal microbiota delivery through oral capsules

    Placebo Capsules (matching MBiotix HBI Caps) + Antibiotics Placebo (matching two active antibiotics) + Standard bowel cleansing (Macrogols). Participants receive matching placebo treatments for both the preparation antibiotics and the oral capsules (MBiotix HBI placebo), along with the same standard bowel cleansing and multi-dose schedule (an initial induction phase and subsequent booster cycles).

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Percentage of Participants Achieving Clinical and Biological Response (Responder Rate) Baseline, Week 13, and Week 26

    The primary outcome is the proportion of participants categorized as "Responders" following multi-dose fecal microbiota transplantation (MBiotix HBI Caps) compared to placebo. A participant is classified as a Responder if they demonstrate objective physiological improvement from Baseline to Week 13 and/or Week 26, defined as meeting at least one of the following two pre-specified criteria:

    * Epigenetic Deceleration: A reduction of at least 5% from baseline in the DunedinPACE biological pace-of-aging algorithm.
    * Attenuation of Inflammaging: A reduction of at least 25% from baseline in at least one circulating systemic inflammatory marker from the predefined panel (provided the marker was significantly elevated at baseline per study inclusion criteria).

    Results will be reported as the percentage of participants in each treatment arm meeting this composite response definition.

Lead sponsor's other trials

Human Biome S.A., most recent start first.

Similar trials

Same condition (Metabolic Syndrome) and phase, most recent start first.